Carboplatin and nab-Paclitaxel as first-line treatment in patients with advanced non-small cell lung cancer with interstitial lung disease (HOT1302)
Phase 2
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000012901
- Lead Sponsor
- Hokkaido Lung Cancer Clinical Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 36
Inclusion Criteria
Not provided
Exclusion Criteria
1) History of Severe drug allergies 2) CVD-IP or other ILD (e.g. pneumoconiosis) with clear cause 3) Active infection 4) Oral steroid or immunosuppressant drug 5) Severe concurrent disease 6) Postive HBs antigen or positive HBs antibody with detectable HBV-DNA 7) Pleural and peritoneal effusion likely to require surgical intervention, or pericardial effusion 8) Symptomatic brain metastasis 9) Active double cancer 10) Pregnant females, possibly pregnant females, females wishing to become pregnant and nursing mothers. Males that are currently attempting to produce a pregnancy 11) Previous treatment with nab-paclitaxel 12) Physician concludes that the patient's participation in this trial is inappropriate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Objective response rate
- Secondary Outcome Measures
Name Time Method Safety, progression-free survival, overall survival